The trial of the Oxford COVID-19 vaccine is about to start in India.

The trial of the Oxford COVID-19 vaccine is about to start in India.

August 3, 2020.

The trial of the Oxford COVID-19 vaccine is about to start in India. India’s number one drug regulatory body DCGI (Drugs Controller General of India) has given consent to Serum Institute of India (SII) which is situated in Pune, to conduct Phase II and III clinical trials of Astra Zeneca vaccine. Oxford University developed the Astra Zeneca COVID-19 vaccine.

A senior Health Ministry official on Monday said, “This will fasten the development of the COVID-19 vaccine”. One government official said in a statement that whether 50,000 new cases reported in the past 24 hours but the case fatality rate (CFR) is continuously decreasing.

Top medical experts and scientists were forced by the global pandemic to develop a safe and effective vaccine against the COVID-19. Since a lot of research has taken place and some experiments have also done. Some experiments have shown fruitful results. According to a report published by the World Health Organization (WHO), at present, near about 26 vaccines are in a clinical evaluation stage. Out of them, six are in a later-stage, phase 3 trial.

According to WHO, a large number of vaccines, near about 139, are in a preclinical evaluation stage. The fatal virus affected Millions of people in the world. To find an appropriate solution against the deadly virus, scientists are doing their best by using different types of methods because the virus is continuously spreading all over the world.

A large number of studies are in progress to evaluate the safety and effectiveness of some of the most advanced vaccines. These important vaccines include the Moderna mRNA vaccine, Pfizer-BioNTech candidate, and Oxford’s Astra Zeneca COVID-19 vaccine, etc. Above all this, Russia claims that they would complete the preparation of mass vaccination against CVOID-19 in October.

Fruitful results are shown by the Covi-shield vaccine on candidates on July 20 and Oxford University made these results public by published in the journal the Lancet. The initial trial results published in the medical journal reported that the vaccine candidate was safe and induced immune reaction against SARS-CoV-2, which causes Covid-19 and protect healthy people from infection.

Adar Poonawalla, CEO, SII, had said, “… As soon as they (DCGI) grant us permission, we will begin with the trials for the vaccine in India. We will soon start manufacturing the vaccine in large volumes”. Poonawalla had also said, “One billion doses of the AstraZeneca Oxford vaccine will be produced over the next one year. The vaccines will be for India and middle-and low-income countries across the world.”

A large number of doses produced and sold globally by the world’s largest vaccine manufacturer, SII, has signed a manufacturing deal with biopharma major AstraZeneca to produce the Oxford vaccine for India and middle-and low-income countries across the world.

The trial of the Oxford COVID-19 vaccine is about to start in India.

Add a Comment

Your email address will not be published. Required fields are marked *